Hypoxia-inducible factor 1： A pivotal regulator in digestive tract tumor progression and therapeutic targeting

doi:10.3877/cma.j.issn.2095-5820.2025.01.006

Abstract

Abstract:

Digestive tract malignancies， a heterogeneous group of tumors affecting the gastrointestinal system and associated organs， pose significant threats to global health. Hypoxia-inducible factor 1 （HIF-1）， an oxygen-sensitive transcriptional activator， dynamically regulates gene expression in response to intracellular oxygen fluctuations. This master regulator drives tumor cell adaptation to hypoxic microenvironments through transcriptional control of critical biological processes， including glycolytic reprogramming and metastatic progression， thereby establishing HIF-1 as an attractive target for gastrointestinal cancer treatment. This article provides a review of the effects of HIF-1 on cellular glucose metabolism， tumor metastasis， and targeted therapy in digestive tract tumor igenesis.

Key words: hypoxia-inducing factor 1, digestive tract tumor, targeted therapy

Yanzi Pan, Jian Xu. Hypoxia-inducible factor 1： A pivotal regulator in digestive tract tumor progression and therapeutic targeting[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2025, 13(01): 41-47.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2025.01.006

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2025/V13/I01/41

References 43

1	XING P， ZHONG Y， CUI X， et al. Natural products in digestive tract tumors metabolism： Functional and application prospects［J］.Pharmacological research， 2023， 191： 106766.
2	AHMAD A， TIWARI R K， SIDDIQUI S， et al. Emerging trends in gastrointestinal cancers： Targeting developmental pathways in carcinogenesis and tumor progression［J］. International review of cell and molecular biology， 2024， 385： 41-99.
3	RAKOTOMALALA A， ESCANDE A， FURLAN A， et al. Hypoxia in solid tumors： How low oxygenation impacts the "Six Rs" of radiotherapy［J］. Frontiers in endocrinology， 2021， 12： 742215.
4	陈影，庄蕾，张丹红，等. 低氧微环境通过TGFBI调控Wnt/β-catenin通路介导胰腺癌化疗耐药及机制研究［J］. 现代肿瘤医学， 2024，32（1）： 42-46.
5	KUBAICHUK K， KIETZMANN T. USP10 contributes to colon carcinogenesis via mTOR/S6K mediated HIF-1α but not HIF-2α protein synthesis［J］. Cells， 2023， 12（12）： 1585.
6	赵斌燕，齐峰. 关于缺氧对细胞及消化道系统影响的研究［J］. 高原医学杂志， 2005， 15（4）： 61-64.
7	YFANTIS A， MYLONIS I， CHACHAMI G， et al. Transcriptional response to hypoxia： The role of HIF-1-associated co-regulators［J］.Cells， 2023， 12（5）： 798.
8	VANDERHAEGHEN T， BEYAERT R， LIBERT C. Bidirectional crosstalk between hypoxia inducible factors and glucocorticoid signalling in health and disease［J］. Frontiers in immunology， 2021， 12：684085.
9	邢英琦，徐静，李琳，等. 缺氧诱导因子（HIF-1）的结构调节与靶基因研究进展［J］. 中国实验诊断学， 2011， 15（1）： 177-179.
10	HE F， XIAO H， CAI Y， et al. ATF5 and HIF1α cooperatively activate HIF1 signaling pathway in esophageal cancer［J］. Cell communication and signaling， 2021， 19（1）： 53.
11	DONG S， LIANG S， CHENG Z， et al. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer［J］. Journal of experimental & clinical cancer research， 2022， 41（1）： 15.
12	LUO Z， TIAN M， YANG G， et al. Hypoxia signaling in human health and diseases： Implications and prospects for therapeutics［J］. Signal transduction and targeted therapy， 2022， 7（1）： 218.
13	石松长，黄昌明. PI-3K［MS1］/Akt信号通路与消化道肿瘤的研究进展［J］. 医学综述， 2007（14）： 1070-1072.
14	杨梦思，周娜，王志钢，等. 转录因子HIF-1α及其信号通路在疾病发生中的作用研究进展［J］.生物技术通报， 2016， 32（8）： 8-13.
15	LIU S， KANG L， SONG Y， et al. Role of the HIF-1α/BNIP3 signaling pathway in recurrent hepatocellular carcinoma and the mechanism of traditional Chinese medicine［J］. Journal of hepatocellular carcinoma，2023， 10： 893-908.
16	SEMENZA G L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations［J］. The journal of clinical investigation， 2013， 123（9）： 3664-3671.
17	李慧杰，齐元富，李秀荣. 缺氧诱导因子1在肿瘤进程中的作用机制研究［J］. 现代肿瘤医学， 2018， 26（18）： 2979-2981.
18	WAN B， CHENG M， HE T， et al. UCHL5 promotes hepatocellular carcinoma progression by promoting glycolysis through activating Wnt/β-catenin pathway［J］. BioMed central cancer， 2024， 24（1）： 618.
19	HU Y， XING Y， FAN G， et al. L-arginine combination with 5-fluorouracil inhibit hepatocellular carcinoma cells through suppressing iNOS/NO/AKT-mediated glycolysis［J］. Frontiers in pharmacology， 2024， 15：1391636.
20	LI Y， XU Q， YANG W， et al. Oleanolic acid reduces aerobic glycolysis-associated proliferation by inhibiting yes-associated protein in gastric cancer cells［J］. Gene， 2019， 712： 143956.
21	Yang Q， Lei X， He J， et al. N4-Acetylcytidine drives glycolysis addiction in gastric cancer via NAT10/SEPT9/HIF-1α positive feedback loop［J］. Advanced science， 2023， 10（23）： e2300898.
22	郭德正，周宗和，罗兴成. HIF-1α与胃肠道肿瘤的关系研究进展［J］.中国民康医学， 2015， 27（8）： 83-85.
23	XU G， LI M， WU J， et al. Circular RNA circNRIP1 Sponges microRNA-138-5p to maintain hypoxia-induced resistance to 5-fluorouracil through HIF-1α-dependent glucose metabolism in gastric carcinoma［J］. Cancer management and research， 2020， 12：2789-2802.
24	赵林林. TCP1α在人胰腺导管腺癌中的表达及对胰腺癌细胞株生物学行为的影响［D］. 济南：山东大学， 2020.
25	CHEN M， CEN K， SONG Y， et al. NUSAP1-LDHA-glycolysis-lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma［J］. Cancer letters， 2023， 567： 216285.
26	SHANG J， XIA Q， SUN Y， et al. Bufalin-loaded multifunctional photothermal nanoparticles inhibit the anaerobic glycolysis by targeting SRC-3/HIF-1α pathway for improved mild photothermal therapy in CRC［J］. International journal of nanomedicine， 2024， 19： 7831-7850.
27	WANG J， WANG X， LIU Z， et al. IGFBP7 promotes gastric cancer by facilitating epithelial-mesenchymal transition of gastric cells［J］.Heliyon， 2024， 10（10）： e30986.
28	LIU M， YANG J， XU B， et al. Tumor metastasis： Mechanistic insights and therapeutic interventions［J］. MedComm， 2021， 2（4）： 587-617.
29	MEI D， ZHU Y， ZHANG L， et al. The role of CTHRC1 in regulation of multiple signaling and tumor progression and metastasis［J］.Mediators of inflammation， 2020， 2020： 9578701.
30	SEO J， JEONG D W， PARK J W， et al. Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells［J］. Communications biology， 2020， 3（1）： 638.
31	DAI W， LI Y， SUN W， et al. Silencing of OGDHL promotes liver cancer metastasis by enhancing hypoxia inducible factor 1 α protein stability［J］. Cancer science， 2023， 114（4）： 1309-1323.
32	王强，郭德正，刘焱伟，等. HIF-1α及STAT3联合预测异时性结直肠癌肝转移［J］. 贵阳医学院学报， 2015， 40（7）： 692-695.
33	XU L， HUAN L， GUO T， et al. LncRNA SNHG11 facilitates tumor metastasis by interacting with and stabilizing HIF-1α［J］. Oncogene，2020， 39（46）： 7005-7018.
34	BIAN Y， YIN G， WANG G， et al. Degradation of HIF-1α induced by curcumol blocks glutaminolysis and inhibits epithelial-mesenchymal transition and invasion in colorectal cancer cells［J］. Cell biology and toxicology， 2023， 39（5）： 1957-1978.
35	MU G， ZHU Y， DONG Z， et al. Calmodulin 2 facilitates angiogenesis and metastasis of gastric cancer via STAT3/HIF-1A/VEGF-A mediated macrophage polarization［J］. Frontiers in oncology， 2021， 11： 727306.
36	LEE PWT， KOSEKI LR， HAITANI T， et al. Hypoxia-inducible factordependent and independent mechanisms underlying chemoresistance of hypoxic cancer cells［J］. Cancers， 2024， 16（9）： 1729.
37	WANG J， WANG X， LIU Z， et al. IGFBP7 promotes gastric cancer by facilitating epithelial-mesenchymal transition of gastric cells［J］.Heliyon， 2024， 10（10）： e30986.
38	IKEDA H， KAKEYA H. Targeting hypoxia-inducible factor 1 （HIF-1）signaling with natural products toward cancer chemotherapy［J］. The journal of antibiotics， 2021， 74（10）： 687-695.
39	WAARTS M R， STONESTROM A J， PARK Y C， et al. Targeting mutations in cancer［J］. The journal of clinical investigation， 2022，132（8）： e154943.
40	CUI C P， WONG C C， KAI A K， et al. SENP1 promotes hypoxiainduced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop［J］. Gut， 2017， 66（12）： 2149-2159.
41	SUN W， LEI X， LU Q， et al. LncRNA FRMD6-AS1 promotes hepatocellular carcinoma cell migration and stemness by regulating SENP1/HIF-1α axis［J］. Pathology research and practice， 2023，243：154377.
42	CHEN J， LI L， FENG Y， et al. MKLN1-AS promotes pancreatic cancer progression as a crucial downstream mediator of HIF-1α through miR-185-5p/TEAD1 pathway［J］. Cell biology and toxicology， 2024， 40（1）：30.
43	LEE S H， GOLINSKA M， GRIFFITHS J R. HIF-1-independent mechanisms regulating metabolic adaptation in hypoxic cancer cells［J］. Cells， 2021， 10（9）： 2371.

[1]	Qin Liu, Hanmin Liu, Liang Xie. Current status of research on the role of matrix metalloproteinases in the pathogenesis of childhood asthma [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 564-568.
[2]	Chuying Wu, Kai Ye. Laparoscopic surgical strategies for different sites of gastrointestinal stromal tumors [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(02): 224-227.
[3]	Honghao Zhu, Xinxiang Fan. Multidisciplinary consultation on difficult cases in Guangdong Urological Association （Phase 18）： female primary urethral carcinoma [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(01): 120-124.
[4]	Weizhou Wu, Qiongren Wang, Xiongyu Zhan, Mingxing Zheng, Yaxian Li. Multidisciplinary consultation on difficult cases in Guangdong Urological Association (Phase 16): sarcomatoid renal cell carcinoma of the left kidney [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 525-529.
[5]	Fei Li, Zaosong Zheng, Peng Wu, Wanlong Tan. Multidisciplinary consultation on difficult cases in Urology of the Guangdong Medical Association (Phase 16): a case of fumarate hydratase deficient advanced renal cell carcinomay [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(04): 410-414.
[6]	Chunlin Wu, Yifu Hou, Kai Chen, Ji Zhao, Shijie Tang, Hongji Yang. Safety and efficacy of hepatic arterial infusion chemotherapy combined with PD-1/TKI for unresectable hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 217-224.
[7]	Botao Chen, Kuan Hu, Xianhai Mao. Tumor microenvironment and systematic treatment of gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 203-208.
[8]	Zhongjing Huang, Lidong Zhang, Ziyi Wu, Junhua Ai. Transformational therapy for unresectable hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 41-45.
[9]	Zhipeng Sun, Bin Shu, Liang Wang, Xin Huang, Pengfei Wang, Guangxin Li, Xiaojuan Wang, Gong Li, Shizhong Yang. Safety and efficacy of radiotherapy combined with targeted neoadjuvant immunotherapy for intrahepatic cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 92-96.
[10]	Weinan Li, Gang Yang, Yongfu Xiong, Qiang Li, Jingdong Li. Preliminary experience of ALPPS after TACE combined with targeted immunotherapy for middle stage and advanced liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(01): 97-101.
[11]	Weijie Chen, Xiaodong He. Progress in immunotargeted therapy for gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 763-768.
[12]	Miaoyan Wei, Jin Xu. Progress and prospects of systemic treatment for pancreatic cancer with distant metastasis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 644-650.
[13]	Xiaofang Shen, Na Zhao, Kejia Li, Yuefei Xiao. Research progress on target antigen discovery and targeted therapy of membranous nephropathy [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2025, 14(01): 53-56.
[14]	Ran Song, Yage Zheng. Evaluation of curative effect and analysis of factors influencing survival rate of unresectable advanced liver cancer treated with lenvatinib combined with TACE [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(02): 120-124.
[15]	Yaqin Ding, Xu Fang, Yancheng Dai. The “One Exemption and Three Priority Policy” based on a tight medical consortium in grassroots digestive tract tumor screening exploration of application effectiveness [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 481-484.

Please choose a citation manager

Content to export